Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | IGLV6-57 | P01721 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30231473 | 0.90 | CA9 (0.54) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL22168566 | 0.87 | ALDH1A1 (0.73) | CA9ALDH1A1HPGDARKDM4E | |
| SCHEMBL30763026 | 0.86 | ALDH1A1 (0.75) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL20839468 | 0.86 | ALDH1A1 (0.75) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL20839066 | 0.86 | ALDH1A1 (0.75) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL30360913 | 0.85 | CA12 (0.48) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL26503877 | 0.85 | CA12 (0.48) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL30231671 | 0.82 | CA12 (0.53) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL30231648 | 0.82 | ALDH1A1 (0.53) | CA9CA12ALDH1A1HPGDAR | |
| SCHEMBL20839106 | 0.82 | ALDH1A1 (0.62) | CA9CA12ALDH1A1HPGDAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, UQCRC2, UQCRC1 | CA9 3495/4885CA12 4467/4885ALDH1A1 1261/4885 |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, UQCRC2, UQCRC1 | CA9 3495/4885CA12 4467/4885ALDH1A1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.